Article may be outdated

This article is 10 days old. Some details may have changed since publication.

HCPLive·4 min read·hard

Fazirsiran and Screening for AATD Liver Disease, With Pavel Strnad, MD

P
Pavel Strnad, MD
Fazirsiran and Screening for AATD Liver Disease, With Pavel Strnad, MD
✦AI Summary

Pooled analysis of two phase 2 clinical trials shows that the siRNA therapy fazirsiran significantly reduces liver Z-AAT levels and inflammation in patients with alpha-1 antitrypsin deficiency-associated liver disease. The treatment demonstrated a favorable safety and efficacy profile over the study period.

Why it matters

This research offers a potential breakthrough for patients suffering from a rare genetic liver disease, providing a targeted molecular therapy to address the underlying cause of the condition.

✦Dive DeeperCreate a free account to unlock

Fazirsiran 200 mg reduced intrahepatic Z-AAT by approximately 90% and improved liver enzymes and portal inflammation compared with placebo in adults with alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD) and a Pi*ZZ genotype, according to pooled analyses of 2 phase 2 trials presented at AASLD The Liver Meeting 2026.¹

Pavel Strnad, MD, of University Hospital RWTH Aachen, presented the data and discussed them in an interview with HCPLive. He noted the individual phase 2 trials of the small interfering RNA (siRNA) therapy were small, and pooling them made the treatment effect clearer.

How Did Fazirsiran Affect Z-AAT Burden and Portal Inflammation?

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in